Business
PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
-- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders -- SOUTH PLAINFIELD, N.J., Oct. 14, 2021
About this update from Ptc Therapeutics, Inc.
[{"type":"text","content":"-- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders --\n\n\nSOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m. ET.\n\n \n \n \n \n \n \n\n \n\"We are committed to being an innovation-based company that brings the best therapies to patients with rare diseases,\" said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. \"Gene therapy holds tremendous promise to treat intractable rare genetic disorders. We have built our capabilities to both perform gene therapy research and to manufacture these biological products. We are proud to have such a talented team and state-of-the-art manufacturing facility here in Hopewell, N.J. that will help expedite bringing these therapies to patients.\" \nJoin the live stream of the ribbon-cutting ceremony at: https://www.ptcbio.com/gene-therapy-manufacturing-in-hopewell-new-jersey/ to hear remarks from featured speakers, including: \nPTC Chief Executive Officer Stuart Peltz PTC Chief Technical Operations Officer Neil Almstead New Jersey Congresswoman Bonnie Watson Coleman New Jersey Economic Development Authority Chief Executive Officer Tim Sullivan Athlete, speaker and spokesperson for the Friedreich's Ataxia Research Alliance Kyle Bryant PTC's Hopewell facility is approximately 220,500 square feet of office, manufacturing and laboratory space, including state-of-the-art technology equipped to handle process development and manufacturing of plasmids and adeno-associated virus (AAV) vectors. The company is also offering world class plasmid DNA and AAV manufacturing services to external partners. PTC's in-house manufacturing, research and development capabilities promote maximum control over the quality, capacity, supply and seamless transition from clinical to commercial development. \nThe Hopewell gene therapy manufacturing center complements PTC's existing operations at the Company's global headquarters in South Plainfield, N.J. and brings the total number of New Jersey-based employees to 625.\nAbout PTC\nPTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinicall...